NASDAQ:CFRX ContraFect Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding ContraFect Co. Please log in to your account or sign up in order to add this asset to your watchlist. $3.10 +0.03 (+0.98%) (As of 07/1/2022 12:00 AM ET) Add Compare Share Today's Range$2.88▼$3.2150-Day Range$2.79▼$4.4552-Week Range$2.11▼$4.54Volume82,317 shsAverage Volume188,105 shsMarket Capitalization$121.92 millionP/E RatioN/ADividend YieldN/APrice Target$8.33 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media ContraFect Stock Forecast (MarketRank)Analyst RatingBuy3.25 Rating ScoreUpside/Downside168.8% Upside$8.33 Price TargetShort InterestBearish5.78% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.39Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.42) to ($0.66) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.1.91 out of 5 starsMedical Sector622nd out of 1,428 stocksPharmaceutical Preparations Industry304th out of 682 stocks 3.7 Analyst's Opinion Consensus RatingContraFect has received a consensus rating of Buy. The company's average rating score is 3.33, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $8.33, ContraFect has a forecasted upside of 168.8% from its current price of $3.10.Amount of Analyst CoverageContraFect has only been the subject of 1 research reports in the past 90 days. Previous Next 0.0 Short Interest Percentage of Shares Shorted5.78% of the float of ContraFect has been sold short.Short Interest Ratio / Days to CoverContraFect has a short interest ratio ("days to cover") of 16.8, which indicates bearish sentiment.Change versus previous monthShort interest in ContraFect has recently increased by 25.44%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldContraFect does not currently pay a dividend.Dividend GrowthContraFect does not have a long track record of dividend growth. Previous Next 0.0 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CFRX. Previous Next 3.0 News and Social Media Coverage News SentimentContraFect has a news sentiment score of 0.39. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.78 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for ContraFect this week, compared to 2 articles on an average week.Search Interest5 people have searched for CFRX on MarketBeat in the last 30 days. This is an increase of 400% compared to the previous 30 days.MarketBeat Follows6 people have added ContraFect to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, ContraFect insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.60% of the stock of ContraFect is held by insiders.Percentage Held by Institutions59.39% of the stock of ContraFect is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for ContraFect are expected to grow in the coming year, from ($1.42) to ($0.66) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of ContraFect is -3.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of ContraFect is -3.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioContraFect has a P/B Ratio of 2.46. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive CFRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ContraFect and its competitors with MarketBeat's FREE daily newsletter. Email Address About ContraFect (NASDAQ:CFRX)ContraFect Corporation, a clinical-stage biotechnology company, discovers and develops therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States. Its lead program includes Exebacase, a lysin, which is in Phase III clinical trials for the treatment of staphylococcus aureus bacteremia. The company also develops CF-296, an engineered lysin, used for treatment of the invasive infections caused by staphylococcus aureus including biofilm-related infections in prosthetic joints and indwelling devices and osteomyelitis; and CF-370, an investigational anti-bacterial therapeutic candidate, which is in Phase 1 clinical trials to treat pseudomonas aeruginosa infections, such as ventilator associated pneumonia, blood stream infections, complicated urinary tract infections, and surgery carry infections. It also initiated an expanded access program to provide Exebacase for the treatment of persistent bacteremia caused by methicillin-resistant staphylococcus aureus in COVID-19 patients. The company has a license agreement with The Rockefeller University to identify novel lysin therapeutic candidates targeting gram-negative pathogens. ContraFect Corporation was incorporated in 2008 and is headquartered in Yonkers, New York.Read More CFRX Stock News HeadlinesJune 27, 2022 | finance.yahoo.comWe're Not Very Worried About ContraFect's (NASDAQ:CFRX) Cash Burn RateJune 14, 2022 | finance.yahoo.comPresentations at ASM Microbe Conference Demonstrate Potential of ContraFect’s Direct Lytic Agents (DLAs) to Address MRSA InfectionsJune 13, 2022 | uk.investing.com70 Stocks Moving In Monday's Mid-Day Session By Benzinga - Investing.com UKJune 13, 2022 | seekingalpha.comDay One Biopharmaceuticals leads healthcare gainers; ContraFect, SciSparc among losers - Seeking AlphaJune 10, 2022 | americanbankingnews.comContraFect Co. Expected to Post FY2023 Earnings of $0.40 Per Share (NASDAQ:CFRX)June 9, 2022 | streetinsider.comPenny Stocks To Buy Today? 3 To Watch With Analyst Targets Up To 675% - StreetInsider.comJune 9, 2022 | americanbankingnews.comContraFect (NASDAQ:CFRX) Upgraded to Strong-Buy by WBB SecuritiesJune 8, 2022 | seekingalpha.comBiopharmaceutical Stocks: Bottoming Process Is Playing Out - Seeking AlphaJune 8, 2022 | benzinga.comWBB Securities Upgrades ContraFect to Strong Buy, Announces $7 Price Target - Benzinga - BenzingaJune 6, 2022 | globenewswire.comContraFect to Present Data Demonstrating the Potential of Its Direct Lytic Agents (DLAs) to Combat MRSA at ASM Microbe 2022 - GlobeNewswireJune 6, 2022 | finance.yahoo.comContraFect to Present Data Demonstrating the Potential of Its Direct Lytic Agents (DLAs) to Combat MRSA at ASM Microbe 2022 - Yahoo FinanceJune 6, 2022 | finance.yahoo.comContraFect to Present Data Demonstrating the Potential of Its Direct Lytic Agents (DLAs) to Combat MRSA at ASM Microbe 2022May 26, 2022 | benzinga.comCFRX: Results from Interim Futility Analysis in July 2022… - Benzinga - BenzingaMay 26, 2022 | finance.yahoo.comCFRX: Results from Interim Futility Analysis in July 2022…May 23, 2022 | finance.yahoo.comEnlivex Appoints Dr. Roger J. Pomerantz to its Board of Directors as Vice Chairman - Yahoo FinanceMay 20, 2022 | globenewswire.comContraFect Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswireMay 20, 2022 | finance.yahoo.comContraFect Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 17, 2022 | finance.yahoo.comContraFect Reports First Quarter 2022 Financial Results and Provides Business Update - Yahoo FinanceMay 16, 2022 | globenewswire.comContraFect Reports First Quarter 2022 Financial Results and Provides Business Update - GlobeNewswireMay 16, 2022 | finance.yahoo.comContraFect Reports First Quarter 2022 Financial Results and Provides Business UpdateMay 13, 2022 | finance.yahoo.comCurative Biotechnology, Inc. Appoints Cary Sucoff to Board of Directors - Yahoo FinanceApril 27, 2022 | benzinga.comContraFect Highlights Presentations Of Data On Its Lysin CF-370 Candidate For Antimicrobial Resistance At European Congress of Clinical Microbiology & Infectious Diseases Apr. 23-26, 2022 - BenzingaApril 27, 2022 | globenewswire.comContraFect Data Presentations at the 32nd Annual ECCMID Meeting Highlight the Potential of Engineered Lysin CF-370 to Improve Clinical Outcomes and Suppress Antimicrobial Resistance Compared to Antibiotics Alone - GlobeNewswireApril 18, 2022 | globenewswire.comContraFect Announces Multiple Presentations of New Data Demonstrating the Potential of Its Direct Lytic Agents (DLAs) to Address Antimicrobial Resistance at the 32nd Annual ECCMID Meeting - GlobeNewswireApril 18, 2022 | finance.yahoo.comContraFect Announces Multiple Presentations of New Data Demonstrating the Potential of Its Direct Lytic Agents (DLAs) to Address Antimicrobial Resistance at the 32nd Annual ECCMID MeetingSee More Headlines Industry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CFRX CUSIPN/A CIK1478069 Webwww.contrafect.com Phone(914) 207-2300FaxN/AEmployees38Year FoundedN/ACompany Calendar Last Earnings5/16/2022Today7/03/2022Next Earnings (Estimated)8/12/2022Fiscal Year End12/31/2022Price Target and Rating Average Stock Price Forecast$8.33 High Stock Price Forecast$9.00 Low Stock Price Forecast$7.00 Forecasted Upside/Downside+168.8%Consensus RatingBuy Rating Score (0-4)3.25 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.89) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-20.28 million Net MarginsN/A Pretax MarginN/A Return on Equity-85.31% Return on Assets-56.33% Debt Debt-to-Equity RatioN/A Current Ratio3.13 Quick Ratio3.13 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.26 per share Price / Book2.46Miscellaneous Outstanding Shares39,330,000Free Float37,917,000Market Cap$121.92 million OptionableNot Optionable Beta0.55 ContraFect Frequently Asked Questions Should I buy or sell ContraFect stock right now? 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for ContraFect in the last year. There are currently 2 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ContraFect stock. View analyst ratings for ContraFect or view top-rated stocks. What is ContraFect's stock price forecast for 2022? 3 analysts have issued 1 year price targets for ContraFect's stock. Their CFRX stock forecasts range from $7.00 to $9.00. On average, they predict ContraFect's share price to reach $8.33 in the next year. This suggests a possible upside of 168.8% from the stock's current price. View analysts' price targets for ContraFect or view top-rated stocks among Wall Street analysts. How has ContraFect's stock price performed in 2022? ContraFect's stock was trading at $2.63 at the start of the year. Since then, CFRX shares have increased by 17.9% and is now trading at $3.10. View the best growth stocks for 2022 here. When is ContraFect's next earnings date? ContraFect is scheduled to release its next quarterly earnings announcement on Friday, August 12th 2022. View our earnings forecast for ContraFect. How were ContraFect's earnings last quarter? ContraFect Co. (NASDAQ:CFRX) issued its earnings results on Monday, May, 16th. The biotechnology company reported ($0.51) EPS for the quarter, missing the consensus estimate of ($0.33) by $0.18. View ContraFect's earnings history. When did ContraFect's stock split? How did ContraFect's stock split work? ContraFect shares reverse split before market open on Tuesday, February 4th 2020. The 1-10 reverse split was announced on Tuesday, February 4th 2020. The number of shares owned by shareholders was adjusted after the closing bell on Monday, February 3rd 2020. An investor that had 100 shares of ContraFect stock prior to the reverse split would have 10 shares after the split. Who are ContraFect's key executives? ContraFect's management team includes the following people: Dr. Roger James Pomerantz F.A.C.P., FACP, M.D., Chairman, CEO & Pres (Age 65, Pay $1.27M)Mr. Michael Messinger CPA, CPA, Chief Financial Officer (Age 47, Pay $620.25k)Dr. Cara M. Cassino M.D., Chief Medical Officer and Exec. VP of R&D (Age 60, Pay $823.72k)Ms. Natalie Bogdanos J.D., Gen. Counsel, Corp. Sec. & Data Protection Officer (Age 53)Mr. Matthew Salamone P.H.R., SPHR, VP of HRDr. Gary Woodnutt, Sr. VP of Translational Sciences & Preclinical Devel. (Age 65) Who are some of ContraFect's key competitors? Some companies that are related to ContraFect include Altimmune (ALT), Centessa Pharmaceuticals (CNTA), Calliditas Therapeutics AB (publ) (CALT), Imago BioSciences (IMGO), Cara Therapeutics (CARA), COMPASS Pathways (CMPS), Amryt Pharma (AMYT), Mersana Therapeutics (MRSN), Nkarta (NKTX), Cogent Biosciences (COGT), Arcturus Therapeutics (ARCT), Intercept Pharmaceuticals (ICPT), Tango Therapeutics (TNGX), Arbutus Biopharma (ABUS) and Aerovate Therapeutics (AVTE). View all of CFRX's competitors. What other stocks do shareholders of ContraFect own? Based on aggregate information from My MarketBeat watchlists, some companies that other ContraFect investors own include SCYNEXIS (SCYX), Inovio Pharmaceuticals (INO), Verastem (VSTM), Vaxart (VXRT), Matinas BioPharma (MTNB), VBI Vaccines (VBIV), Novavax (NVAX), Cidara Therapeutics (CDTX), Gilead Sciences (GILD) and Dynavax Technologies (DVAX). What is ContraFect's stock symbol? ContraFect trades on the NASDAQ under the ticker symbol "CFRX." How do I buy shares of ContraFect? Shares of CFRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is ContraFect's stock price today? One share of CFRX stock can currently be purchased for approximately $3.10. How much money does ContraFect make? ContraFect (NASDAQ:CFRX) has a market capitalization of $121.92 million. The biotechnology company earns $-20.28 million in net income (profit) each year or ($0.89) on an earnings per share basis. How many employees does ContraFect have? ContraFect employs 38 workers across the globe. How can I contact ContraFect? ContraFect's mailing address is 28 WELLS AVENUE 3RD FLOOR, YONKERS NY, 10701. The official website for ContraFect is www.contrafect.com. The biotechnology company can be reached via phone at (914) 207-2300 or via email at mmessinger@contrafect.com. This page (NASDAQ:CFRX) was last updated on 7/3/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here
